Literature DB >> 11466672

Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates.

S L Glaser1, R F Dorfman, C A Clarke.   

Abstract

BACKGROUND: The reliability of Hodgkin disease (HD) diagnosis and histologic classification is an ongoing concern but has not been evaluated in a population-based case series in 20 years. Yet, diagnostic error in cancer registry data used in surveying HD occurrence may produce statistics that misrepresent incidence, mortality, or survival.
METHODS: Uniform pathology review was attempted for all 395 women ages 19--79 years with incident HD reported to a population-based cancer registry in 1988--94. Agreement between original registry and review diagnoses was measured with positive predictive values and kappa statistics. Incidence rates and survival probabilities were computed based on registry and review diagnoses.
RESULTS: Registry and review diagnosis agreed for 245 of the 362 reviewed cases. Positive predictive values varied by histologic subtype (nodular sclerosis, 95%; lymphocyte predominance, 69%; mixed cellularity, 58%; lymphocyte depletion, 0%; not otherwise specified, 40%), but agreement was good overall (kappa, 0.66, 95% confidence interval, 0.56--0.76). Eleven patients were determined not to have HD; all were older than age 44 years. Hodgkin disease incidence rates differed for original and review diagnoses only in older women, for whom registry rates slightly overestimated incidence. Five-year survival rates did not differ for registry and review data overall or by age group.
CONCLUSIONS: For most adult women patients, the diagnosis of HD was confirmed on review, reflecting the very good agreement between registry and review diagnoses for nodular sclerosis, the most common subtype. Thus, cancer registry statistics for this time period can provide accurate estimates of disease patterns for HD overall and for the nodular sclerosis variant. For other histologic subtypes, rates may be unreliable, and HD occurrence overall may be less dependable in populations with larger proportions of these subtypes. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Year:  2001        PMID: 11466672     DOI: 10.1002/1097-0142(20010715)92:2<218::aid-cncr1312>3.0.co;2-6

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  A simple model for potential use with a misclassified binary outcome in epidemiology.

Authors:  S W Duffy; J Warwick; A R W Williams; H Keshavarz; F Kaffashian; T E Rohan; F Nili; A Sadeghi-Hassanabadi
Journal:  J Epidemiol Community Health       Date:  2004-08       Impact factor: 3.710

2.  Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation.

Authors:  Christina A Clarke; Sally L Glaser; Scarlett L Gomez; Sophia S Wang; Theresa H Keegan; Juan Yang; Ellen T Chang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

Review 3.  Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph).

Authors:  M Kamper-Jørgensen; K Rostgaard; S L Glaser; S H Zahm; W Cozen; K E Smedby; S Sanjosé; E T Chang; T Zheng; C La Vecchia; D Serraino; A Monnereau; E V Kane; L Miligi; P Vineis; J J Spinelli; J R McLaughlin; P Pahwa; J A Dosman; M Vornanen; L Foretova; M Maynadie; A Staines; N Becker; A Nieters; P Brennan; P Boffetta; P Cocco; H Hjalgrim
Journal:  Ann Oncol       Date:  2013-06-19       Impact factor: 32.976

Review 4.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 5.  The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.

Authors:  Máire A Duggan; William F Anderson; Sean Altekruse; Lynne Penberthy; Mark E Sherman
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

6.  Lymphocyte-depleted classic Hodgkin lymphoma-a neglected entity?

Authors:  Daniel Benharroch; Amalia Levy; Jacob Gopas; Martin Sacks
Journal:  Virchows Arch       Date:  2008-10-29       Impact factor: 4.064

7.  The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates.

Authors:  R F Jarrett; A S Krajewski; B Angus; J Freeland; P R Taylor; G M Taylor; F E Alexander
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

8.  Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California populations.

Authors:  Sally L Glaser; Margaret L Gulley; Christina A Clarke; Theresa H Keegan; Ellen T Chang; Sarah J Shema; Fiona E Craig; Joseph A Digiuseppe; Ronald F Dorfman; Risa B Mann; Hoda Anton-Culver; Richard F Ambinder
Journal:  Int J Cancer       Date:  2008-10-01       Impact factor: 7.396

9.  Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.

Authors:  Diponkar Banerjee
Journal:  Adv Hematol       Date:  2011-01-18

10.  Endometrial stromal sarcoma: a population-based analysis.

Authors:  J K Chan; N M Kawar; J Y Shin; K Osann; L-M Chen; C B Powell; D S Kapp
Journal:  Br J Cancer       Date:  2008-09-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.